The earnings call reflects a mixed sentiment. While there are strong sales growth, successful restructuring efforts, and positive clinical data, the regulatory challenges for DrugSorb ATR and increased operating expenses pose significant concerns.

Company Guidance -

Q3 2025

In the second quarter of 2025, Cytosorbents Corp reported product sales of $9.6 million, reflecting a 9% year-over-year increase and a 4% increase on a constant currency basis. The company's gross margin held steady at approximately 71%, although there was a slight decline from the previous year's 73.5%, attributed primarily to inventory write-offs. The German commercial team saw notable improvements, with a 22% growth year-over-year and sequentially, contributing to the overall performance. Operating expenses increased slightly due to unique strategic charges, but the company remains focused on reducing core business operating costs to drive towards breakeven by the end of the year. Cytosorbents also reported a net income of $1.9 million for the quarter, but when adjusted for currency changes and non-cash items, the adjusted net loss was $3.7 million. The company continues to prepare for a potential North American launch of DrugSorb ATR, anticipating regulatory decisions from both the FDA and Health Canada by the end of 2025.

Product Sales Growth

Cytosorbents reported product sales of $9.6 million in Q2 2025, representing a 9% year-over-year increase and a 4% increase on a constant currency basis.

German Commercial Team Reorganization Success

The German commercial team saw a 22% year-over-year and sequential growth, indicating successful reorganization and strategic realignment.

Strong Gross Margin

Gross margin performance remained solid at approximately 71%, indicating strong operational efficiency.

Positive Data on CytoSorb for Sepsis Treatment

CytoSorb demonstrated significant reductions in severe CABG-related bleeding and large transfusion events in clinical settings, strengthening its clinical utility.

Net Income Achievement

The company reported a net income of $1.9 million for Q2 2025, compared to a net loss of $4.3 million in the prior year.

Cytosorbents (CTSO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTSO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.04 / -	-0.04	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / 0.03	-0.08	137.50% (+0.11)	―
May 14, 2025	2025 (Q1)	- / -0.02	-0.12	83.33% (+0.10)
Mar 31, 2025	2024 (Q4)	-0.07 / -0.02	-0.12	83.33% (+0.10)
Nov 07, 2024	2024 (Q3)	-0.06 / -0.04	-0.21	80.95% (+0.17)
Aug 13, 2024	2024 (Q2)	-0.10 / -0.08	-0.14	42.86% (+0.06)
May 09, 2024	2024 (Q1)	-0.12 / -0.12	-0.17	29.41% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.14 / -0.12	-0.01	-1100.00% (-0.11)	―
Nov 09, 2023	2023 (Q3)	-0.12 / -0.21	-0.28	25.00% (+0.07)	―
Aug 01, 2023	2023 (Q2)	-0.11 / -0.14	-0.25	44.00% (+0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTSO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.89	$1.00	+12.36%
May 14, 2025	$0.81	$0.83	+2.47%
Mar 31, 2025	$1.00	$1.00	0.00%
Nov 07, 2024	$0.90	$0.74	-17.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytosorbents Corp (CTSO) report earnings?

Cytosorbents Corp (CTSO) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Cytosorbents Corp (CTSO) earnings time?

Cytosorbents Corp (CTSO) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTSO EPS forecast?

CTSO EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing